Phi Pharma, board of directors

Board of directors

Marco Renoldi, MD (Chairman)

Dr. Renoldi brings over 35 years of operational and leadership experience in various executive roles in the biopharma industry. His most recent position was Chief Operating Officer at Nordic Nanovector, a public clinical stage company headquartered in Oslo (2014-2021). Prior to joining Nordic Nanovector, Marco served as SVP, Chief Commercial Officer at Shionogi (2012-2014). From 2003 to 2012 he held executive roles at Amgen, first as Managing Director of the Italian affiliate and subsequently as ED, Oncology Franchise Head for the International Region. Prior to Amgen, Marco held national and global R&D and business roles at Novartis, Searle, and Pharmacia. Following his retirement in December 2021, Marco has continued to engage in support of biotech start-up businesses as Board member and External Adviser, through his own company Bonafide Associates. He also sits in the Board of Respinor, a med-tech company headquartered in Oslo. Marco holds a medical degree from the University of Milan and an MBA from Fondazione IDI/Assolombarda. Marco is an Italian citizen, and he resides in Zug, Switzerland.

Luigi Costa (Board Member)

Luigi Costa brings over 25 years of operational and leadership experience in the global pharmaceutical and biotech industry. As Chief Executive Officer of Nordic Nanovector, a biotech company focusing on novel targeted therapeutics in hematology and oncology, Luigi led one of the largest European biotech IPOs of 2015 of $ 60M and a multi subscribed private placement in 2016 of over Euro 65M, after increasing the company’s market capitalization of over 30 times in less than 30 months.
He also served as Board Member and Member of the Audit Committee of Oncopeptides AS (Sweden), which went public in 2017 for Euro 68M. Previously, Luigi was Regional Head International at Onyx Pharmaceuticals, acquired by Amgen in 2014, where he led the company’s international organization and the launch of its multiple myeloma drug, Kyprolis®, outside the USA. Prior to joining Onyx Pharmaceuticals, Luigi held several leadership positions with Amgen and Eli Lilly both in Europe and in the US. Luigi holds a BSc in Business Administration and an MBA from Bocconi Business School and Manchester Business School.

Emmanuel Savioz (Co-founder, Board member)

Emmanuel Savioz has been in financing and business development since 15 years. He is the Co-founder and Board Member of HYT SA and Preciflex SA. He built a USD 30 million business in Seoul with a local partner for a Swiss industrial company and arranged CHF 62 million of equity financing for high tech companies in Switzerland. Previously, he worked in New York as an investment banker in mergers and acquisitions handling large international transactions in consumer goods and healthcare. Emmanuel Savioz is former member of the Admission Committee of the MBA Program at IMD in Lausanne, Switzerland, and holds an MBA from the Haas School of Business, University of California at Berkeley, USA.

Patrick Berdoz (Co-founder, Board member)

Patrick Berdoz has been a serial entrepreneur for more than 20 years in various innovative sectors (medtech, watch and real estate). He is the Co-founder and Chairman of HYT SA and Preciflex SA. Between 1994 and 2007, he was the CEO and Chairman of Precimed Group which grew from 17 employees to 700. In 1998, he established Precimed in the USA, Japan and then China. He led the successful trade sale of Precimed Group to a publicly traded company in the US. He began his career at 28 as CEO and owner of Viso Medical, an intravenous therapy Company (Neuchâtel, Switzerland) that he sold at age 34 to a French Pharma. Patrick Berdoz is an economist from HEG in Lausanne, Switzerland.

Christophe Bonny, PhD (Co-founder, Board member)

Dr. Bonny has over 20 years’ experience in the field of molecular biology and signalling pathways, has authored over 70 scientific publications and is an inventor on several patents. He works as CSO of Enterome in Paris France since 2016. He discovered D-JNKI, a cell permeable peptide inhibitor of the JNK protein, which formed the basis for the creation of the biotechnology company Xigen SA in 2003. In 2005, he received the Pfizer Research Prize for this discovery and the molecule is currently in Phase III clinical trials for hearing loss. Between 2012 and 2016, he was CSO of Bicycle Therapeutics in Cambridge UK. Between 2006 and 2011, he was CSO of Xigen SA (Switzerland). Previously, he also held the position of Head of Research of the Medical Genetics unit at Lausanne University Hospital (Switzerland) and a prior to this was a Research Fellow at Northwestern University (US). Dr. Bonny obtained a PhD from the University of Neuchâtel (Switzerland), and completed a business and entrepreneurship program at Babson College (US).